Tector Therapeutics

Tector Therapeutics is a preclinical-stage biotech company developing a novel platform for targeted delivery of gene-editing to cancer cells. By repurposing the natural capabilities of T cells, Tector addresses major limitations of existing gene therapy systems—such as poor tissue specificity and immunogenicity. Our initial focus is on hard-to-treat cancers like diffuse large B-cell lymphoma, with plans to expand to other cancers.